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In this issue of the Journal, Guazzi et al. (1) report the very
provocative effects of an acute insulin infusion on pulmonary
function and exercise performance in patients with well-
controlled type 2 diabetes (HgbA1C 6.2%) and heart failure
(HF). Intravenous insulin (10 IU) had no effect on resting
ejection fraction but did decrease resting systolic pulmonary
artery pressure. Insulin improved resting lung diffusing
capacity for carbon monoxide (DLCO) and its subcompo-
nents alveolar-capillary membrane diffusion capacity (DM)
and pulmonary capillary volume available for gas exchange
(Vc). Insulin also had a marked effect on exercise with an
increase in the workload and the oxygen consumption
(VO2) both at anaerobic threshold (AT) and peak exercise.
There was also an increase in both aerobic (VO2 increase
per watt of work increase [VO2/W]) and ventilatory effi-
ciency (increase in ventilation with respect to carbon dioxide
production [VE/VCO2]). The changes persist at least
6 h. Peak VO2, VE/VCO2, VO2/W, and DLCO are all
See page 1044
predictors of mortality in HF. However, which measure-
ment is the best predictor of mortality in HF is uncertain.
Can the effects of intravenous insulin be sustained and
would this decrease the mortality in HF subjects with
diabetes? Even more provocative, given the mild nature of
the diabetes in these subjects, how would intravenous
insulin affect HF patients without diabetes?
DLCO varies with lung volumes, hemoglobin and, less
well-known, cardiac output. In normal subjects, additional
lung capillaries are recruited during exercise in proportion to
the increased cardiac output and DLCO can double. In HF,
the resting DLCO is reduced but it increases during exercise
in proportion to cardiac output. In primary lung diseases
like pulmonary fibrosis, there is an inability to recruit
additional pulmonary capillaries and the DLCO fails to
increase during exercise (2). In HF, DLCO also correlates
with peak VO2 and pulmonary vascular resistance (3).
Guazzi et al. (1) reported that insulin increased the DLCO
and the change in DLCO correlated with the improvement
in peak VO2 and VE/VCO2. The magnitude of improve-
ment in the peak VO2 with insulin is similar to three
months of exercise training. The change in peak VO2
(14%) is greater than angiotensin-converting enzyme
inhibitors (minimal), beta-blockers ( 0 to 5%), and cardiac
resynchronization therapy (7%). Although the authors
noted a correlation between an improvement in DLCO and
both peak VO2 and VE/VCO2, they appropriately caution
that this association may not be causal. In normal subjects,
DLCO is associated with rest cardiac index (4) but not peak
VO2 (5). DLCO is unaltered by exercise training (6) and
may worsen after cardiac transplant whereas peak VO2 is
increased (7). Angiotensin-converting enzyme inhibitors
increase peak VO2 and DLCO, whereas hydralazine/nitrates
have an even greater increase in peak VO2 but the DLCO is
unchanged (8). It is more likely the change in peak VO2 and
VE/VCO2 is secondary to improved endothelial function
and redistribution of blood flow at the pulmonary and
skeletal muscle capillary level and not a direct result of the
change in DLCO.
The Framingham study has shown diabetes increases the
risk of developing HF twofold in men and fourfold in
women (9). Conversely, patients with HF are at an in-
creased risk of developing diabetes mellitus (10). The
interrelationships of these observations are complex and
uncertain but are probably due to neurohormonal and
cytokine activation that is present in both diabetes and HF.
Patients with type 2 diabetes have low-grade inflamma-
tion with elevation of proinflammatory cytokines, including
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-),
endothelin 1, C-reactive protein, and norepinephrine (11).
Insulin resistance is associated with a reduction in type I
skeletal muscle fibers (12), reduced skeletal muscle blood
flow, and glucose uptake during exercise (13), resulting in
earlier anaerobic threshold and a reduced peak VO2 (14,15).
These changes at the skeletal muscle level may be mediated
by reduced nitric oxide (NO)-mediated vasodilation or by
alteration in substrate utilization with decreased skeletal
muscle glucose oxidation (16). In sepsis, endotoxin activates
proinflammatory cytokines, induces insulin resistance (17),
and impairs left ventricular systolic function (18). Insulin
has been proposed to be a potent antiinflammatory that
suppresses TNF-, IL-6, intercellular adhesion molecule-1,
macrophage chemoattractant protein-1, and nuclear
factor-B (19) and enhances NO synthesis (20). In venti-
lated intensive care unit patients, 87% of whom did not have
diabetes, an insulin infusion to normalize glucose to 80 to
110 mg/dl reduced markers of inflammation, infections,
transfusions, and mortality (21).
Heart failure is an inflammatory state with elevation of
many of the same neurohormones and cytokines as seen in
type 2 diabetes, albeit at much higher levels (22). The
cytokine elevations are prognostically important, especially
IL-6 and TNF- receptors (23). Interestingly, the benefi-
cial effect of insulin on HF is not a new finding (24),
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although previous investigations have focused on left ven-
tricular performance rather than skeletal and pulmonary
performance. The mechanisms for these findings are not
clear. In HF, diabetes confers an additional risk of death,
but whether this observation is independent of or mediated
by alterations in exercise variables, neurohormones, and
cytokines is uncertain (25). Is it possible the beneficial
effects reported with insulin therapy in HF are related to its
suppression of common cytokines, endothelin 1, free fatty
acids, or norepinephrine, all of which also worsen insulin
resistance?
In HF, there are marked alterations in the skeletal
muscle, including a decrease in the efficient type I highly
oxidative fibers, oxidative enzymes, and mitochondrial den-
sity and an increase in the inefficient type IIb glycolytic
fibers as well as muscle and capillary atrophy (26). Diabetes
has many of the same skeletal muscle changes along with
impaired insulin-mediated glucose uptake by type I fibers
(12). Insulin stimulates glucose uptake via GLUT4 in
proportion to the oxidative capacity of the muscle fiber, type
I type IIa type IIb (27). In animals and humans, the O2
consumption in type I fibers is only 40 to 50% of type II
fibers performing the same work (28). During exercise,
there are alterations in the skeletal muscle fiber type
recruitment and blood flow. At low levels of exercise, type I
fiber utilization predominates (oxidative) and lactate levels
are low. At levels of exercise above the anaerobic threshold,
type II glycolytic fibers are recruited, which is associated
with an increase in lactate production (29). Type I fibers are
more sensitive than type II to the vasoconstrictor effects of
norepinephrine (30) and to insulin-mediated glucose uptake
(12). In HF and diabetes, it is anticipated that the high
sympathetic activity and cytokines would divert blood flow
from the efficient type I fibers to inefficient type IIb fibers
whereas insulin would improve skeletal muscle blood flow
(31) and glucose uptake predominantly by oxidative type I
fibers (32).
Aerobic efficiency in HF is a complex interaction that
requires the measurement of VO2 during exercise and
recovery. Previous investigators have suggested as HF
progresses, there is a compensatory increase in aerobic
efficiency as measured by a lower VO2/W (33). However,
HF patients are not more aerobically efficient (lower
VO2/W) but rather accumulate a large oxygen debt (recov-
ery VO2/W) that must be repaid after the completion of
exercise such that the total oxygen cost of exercise which
includes the recovery VO2/W, is actually increased (34).
Guazzi and colleagues report only the VO2/W during
exercise. It is anticipated that insulin improves skeletal
muscle blood flow to type 1 fibers (31), possibly because of
enhanced NO (20,35) and increased glucose uptake/
oxidation (12,32). This permits a longer duration of “aero-
bic” exercise before the recruitment of type IIb glycolytic
fibers. This is supported by the observation that all the
increase in workload and VO2 occurred from rest to AT
whereas the workload and VO2 from AT to peak was
unchanged in the current study. It is further anticipated that
the 21% improvement in aerobic efficiency will be accom-
panied by a similar decrease in the oxygen debt (34).
As previously noted, it is tempting to speculate about the
effect of insulin in HF subjects with insulin resistance who
do not have diabetes. If insulin has such a beneficial effect in
HF, why has it taken so long to make this observation?
Subcutaneous insulin has been used as a standard of care for
over 80 years, and yet it has been only relatively recently that
improvements in HF and myocardial infarction have been
shown in clinical trials to be improved by insulin (36).
Perhaps the answer is that cardiovascular benefit can be best
attained using intravenous insulin as opposed to the more
common subcutaneous insulin delivery. If this is the case,
would intraperitoneal insulin delivery be an option for
severe HF with diabetes? Implantable pumps for the treat-
ment of diabetes are now being developed, but perhaps this
is something that could also be used for HF. It seems to us
that for there to be real progress in this area, advancement
in two areas will be required. First, the findings of Guazzi et
al. (1) need to be further clarified and the exact mechanisms
of improvement with insulin in HF will need to be docu-
mented. Furthermore, cardiologists will need to work closer
with endocrinologists to become more comfortable with the
use of insulin, for both inpatients and outpatients. If we can
succeed with both of these goals, there is the potential to
make major contributions for this growing patient popula-
tion.
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